Last updated on January 2020

Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF


Brief description of study

The study will assess the safety of different dose regimens of HepaStem in cirrhotic Patients with ACLF or with acute decompensation at risk of developing ACLF up to Day 28 of the active study period.

Clinical Study Identifier: NCT02946554

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.